trial summary · NCT07644650
Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors
A Phase 1, Multiregional, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MST-168, in Participants With Advanced Solid Malignant Tumors
Trial record from the TrialBase DB dataset, status RECRUITING, condition Neoplams, sponsored by Mabsoft Therapeutics (Shanghai) Co., Ltd.. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors. The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic effects, and preliminary efficacy of MST-168 in participants with target-driven advanced solid tumors. MST-168 is an investigational ADC.
Source record: https://clinicaltrials.gov/study/NCT07644650
Facts
| registry id | NCT07644650 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Neoplams |
| sponsor | Mabsoft Therapeutics (Shanghai) Co., Ltd. |
| sponsor class | INDUSTRY |
| enrollment | 420 |
| start date | 2026-10-26 |
| primary completion | 2028-06-30 |
| completion | 2030-06-30 |
| results posted | not reported |
Conditions
- Neoplams
Interventions
- MST-168
Countries
- China
Intervention types: BIOLOGICAL
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.